{
    "clinical_study": {
        "@rank": "70780", 
        "brief_summary": {
            "textblock": "The purpose of this research study is to evaluate the safety, tolerability, and efficacy of\n      Interferon gamma-1b (IFN-gamma 1b) when administered by subcutaneous injection over a period\n      of 4 weeks to patients with mild-to-moderate cystic fibrosis.   Additionally, preliminary\n      assessments on the effects of IFN-gamma 1b on lung function and other indicators of health\n      will be made."
        }, 
        "brief_title": "Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis", 
        "completion_date": {
            "#text": "March 2003", 
            "@type": "Actual"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  At least 6 years of age\n\n          -  Diagnosis of cystic fibrosis (against certain criteria)\n\n          -  Able to perform pulmonary (lung) function tests and participate in induced sputum\n             procedures\n\n          -  Pulmonary function values must meet certain minimal requirements\n\n          -  Must have acceptable laboratory test results\n\n          -  Cannot be on certain medications during and immediately prior to study\n\n          -  Cannot have a history of unstable or deteriorating cardiac or neurologic disease"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "51", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00043342", 
            "org_study_id": "GICF-002"
        }, 
        "intervention": {
            "description": "100 or 200 mcg, SQ, 3x per week", 
            "intervention_name": "interferon gamma-1b", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-gamma", 
                "Interferons"
            ]
        }, 
        "keyword": [
            "cystic fibrosis", 
            "pulmonary impairment"
        ], 
        "lastchanged_date": "October 29, 2007", 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Study of Interferon Gamma-1b by Subcutaneous Injection for the Treatment of Patients With Cystic Fibrosis", 
        "overall_official": {
            "affiliation": "InterMune", 
            "last_name": "Steven Porter, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_outcome": {
            "measure": "change in sputum neutrophil count", 
            "time_frame": "4 weeks"
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043342"
        }, 
        "secondary_outcome": {
            "measure": "change in predicted FEV1, sputum bacterial density, sputum levels of free neutrophil elastase, DNA and IL-8", 
            "time_frame": "4 weeks"
        }, 
        "source": "InterMune", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InterMune", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007"
    }, 
    "geocoordinates": {}
}